Vaccines and vaccination

New England Journal of Medicine

Volumn 345, Issue 14, 2001, Pages 1042-1053

  Ada, Gordon ^a  

^a Biology and Environment   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EDIBLE VACCINE; IMMUNOLOGICAL ADJUVANT; VACCINE; VIRUS VECTOR;

ALZHEIMER DISEASE; ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; CANCER; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; IMMUNE RESPONSE; INFECTION; PRIORITY JOURNAL; REVIEW; TRANSGENIC PLANT; VACCINATION; WORLD HEALTH ORGANIZATION;

ALZHEIMER DISEASE; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; HUMANS; IMMUNIZATION PROGRAMS; NEOPLASMS; TREATMENT OUTCOME; VACCINATION; VACCINES; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SUBUNIT; VIRUS DISEASES; WORLD HEALTH;

EID: 0035807593     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra011223     Document Type: Review

References (93)

1. Imperfect memory and the development of Haemophilus influenzae type b disease
2. Summary of notifiable diseases, United States, 1998
3. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
4. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children
5. The cellular basis for lack of antibody responses to hepatitis B vaccine in humans
6. The role of epidemiology in the development of a vaccination programme
7. Intussusception among infants given an oral rotavirus vaccine
8. Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: A review of claims submitted to the National Vaccine Injury Compensation Program
9. Vaccines today
10. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children
11. Measles-mumps-rubella immunisation, autism and inflammatory bowel disease: Update
12. MMR vaccine: The continuing saga
13. Progress towards poliomyelitis eradication: WHO eastern Mediterranean region
14. Rotavirus vaccines: Success by reassortment
15. Global epidemiology of sexually transmitted diseases
16. The immune system
17. The immune response to influenza infection
18. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
19. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
20. HIV-specific CTL activity in an HIV-exposed but uninfected infant
21. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers
22. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients
23. Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women
24. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
25. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids
26. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques
27. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
28. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
29. Adenovirus vaccines
30. 55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues
31. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women
32. Influenza viruses: General features
33. Cellular immune responses to HIV
34. Plant biotechnology: New products and applications
35. Plant viral vectors based on tobamoviruses
36. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans
37. Science, medicine, and the future: Susceptibility to infection
38. Advances in vaccine delivery: Transcutaneous immunization
39. Efficacy trial of malaria vaccine SPf66 in Gambian infants
40. Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulation complexes (ISCOMS)
41. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages
42. Induction of protective cytotoxic T cells with viral proteins
43. Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles
44. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian aboriginal population
45. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes
46. The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine
47. A wholly synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types
48. Vaccinia virus: A selectable eukaryotic cloning and expression vector
49. Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus
50. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
51. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
52. Development of a preventive vaccine for Ebola virus infection in primates
53. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression
54. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection
55. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox
56. DNA vaccines
57. Causing a commotion in the blood: Immunotherapy progresses from bacteria to bacterial DNA
58. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
59. A toll for DNA vaccines
60. Generation of enhanced immune responses by consecutive immunisation with DNA and recombinant fowlpox virus
61. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
62. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
63. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
64. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
65. Merck reemerges with a bold AIDS vaccine effort
66. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
67. Containing HIV after infection
68. Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis
69. HIV and pandemic influenza virus: Two great infectious disease challenges
70. Challenges and opportunities for development of an AIDS vaccine
71. A universal influenza A vaccine based on the extracellular domain of the M2 protein
72. Applications of molecular microbiology to vaccinology
73. Gene may promise new route to potent vaccines
74. Oral tolerance: Mechanisms and therapeutic applications
75. Tolerance and autoimmunity
76. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
77. HVP6b virus like particles are potent immunogens without adjuvant in man
78. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells
79. Dendritic cell vaccines for cancer immunotherapy
80. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells
81. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
82. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
83. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
84. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease
85. Alzheimer's amyloid hypothesis gains support
86. Further progress on a β-amyloid vaccine
87. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy